Cantor Fitzgerald analyst Elemer Piros reiterated an Overweight rating and $65 price target on PolarityTE (NASDAQ: COOL) following Q3 results.

Piros notes additional clinical outcomes data will be presented at the American Society of Plastic Surgeons Conference, taking place from Sept.28-Oct.1 in Chicago.

PolarityTE remains focused on the commercialization of SkinTE, corporate growth (with now over 100 employees, 50% of which having advanced degrees), and extending the pipeline to other TE programs and additional related technology derivative, the analyst notes. During the earnings call, PolarityTE announced that the majority of SkinTE sales come from the two regions with the highest number of sales reps.

Piros sees an eventful 12-18 months for the company. "Over the course of the next year and a half, PolarityTE has many upcoming catalysts and commercialization plans. These include expanding the use of SkinTE in the U.S., and expanding globally in Asia and Europe with manufacturing and commercialization. Additionally, PolarityTE could register OsteoTE as a human cell tissue product for commercial use (with a limited release in end-2018/early 2019). PolarityTE anticipates additional presentations and publications in the next 12-18 months. This includes results from the head to head clinical trial comparing SkinTE vs. split thickness skin grafts towards the end of 2019."

For an analyst ratings summary and ratings history on PolarityTE click here. For more ratings news on PolarityTE click here.

Shares of PolarityTE closed at $20.45 yesterday.